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Although cancer therapies have experienced great success nowadays, yet the associated toxic response and free radicals formation
have resulted in signiﬁcant number of treatment-induced deaths rather than disease-induced fatalities. Complications of
chemotherapy have forced physicians to study antioxidant use as adjunctive treatment in cancer. This study aimed to evaluate
the antioxidant role of vitamin E and N-acetyl cysteine (NAC) in overcoming treatment-induced toxicity in acute lymphoblastic
leukaemia (ALL) during the intensive period of chemo-/radiotherapy, almost the ﬁrst two months of treatment. Forty children
newly diagnosed with ALL were enrolled in this study. Twenty children (group I) have taken vitamin E and NAC supplementations
withchemotherapyandtheothertwentychildren(groupII)havenottakenanyadjuvantantioxidanttherapy.Theywereevaluated
clinically for the occurrence of complications and by the laboratory parameters (blood levels of glutathione peroxidase (Glu.PX)
antioxidantenzyme,malondialdehyde(MDA),tumornecrosisfactor-α(TNF-α),liverenzymes,andbonemarrowpicture).Results
revealed reduced chemotherapy and radiotherapy toxicity as evidenced by decreasing level of MDA, increasing level of Glu.Px and
decreased occurrence of toxic hepatitis, haematological complications, and need for blood and platelet transfusions in group I
compared to group II. We can conclude that vitamin E and NAC have been shown to be eﬀective as antioxidant adjuvant therapy
in children with ALL to reduce chemo-/radiotherapy-related toxicities during the initial period of treatment.
Copyright © 2009 Youssef Al-Tonbary et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Cancer survivors are increasing nowadays; many of them
are highly motivated to seek information about dietary
supplement use and complementary nutritional therapies
to improve their response to treatment [1]. Leukemia and
lymphoma therapy, especially in children, is the success
storyofcontemporarycancertreatment.Thereiswidespread
consensus that, with survival projections as good as they
are, the emphasis is shifting towards improving tolera-
bility and reducing side eﬀects from treatment. Children
undergoing treatment for acute lymphoblastic leukaemia
(ALL) receive multiagent chemotherapy; many of them
(cytosine arabinoside, doxorubicin, cyclophosphamide, and
methotrexate) are associated with free radical production
may aﬀect the antioxidant status during therapy [2]. Also
hepatic and hematological complications are very common
due to multiagent chemotherapy especially during the initial
intensive period of induction; usually these complications
cause discontinuation of therapy, prolong the duration of
stay in hospitals, and may aﬀect the overall prognosis and
outcome of the disease. There is a debate about the concur-
rentuseofantioxidantswithcytotoxictherapies[3].Itistrue
that much remains unknown concerning antioxidants, their
mode of action, and possible interaction. Vitamin E (alpha
tocopherol succinate) as antioxidant has generated some2 Advances in Hematology
interest as an adjunctive cancer therapy due to its remarkable
lackoftoxicityinvivo[4].Ifgivenwithomega3fattyacidsof
ﬁsh oil, it may prolong survival in patients with generalized
malignancy [5]. Another antioxidant is N-acetylcysteine
(NAC) which is the acetylated form precursor of L-cysteine
and reduced glutathione. It was used as a mucolytic agent in
respiratory illness as well as an antidote for acetaminophen
hepatotoxicity but recently used as complementary therapy
of cancer [6, 7].
This study aims to evaluate the role of vitamin E and
N-acetylcysteine as adjuvant therapy in children with ALL
during the induction and CNS intensiﬁcation phases of
chemotherapy, the initial two months of treatment, and their
possible role in prevention and control of hepatic and hema-
tologicalcomplications(bonemarrowhypoplasiaandfebrile
neutropenia) associated with the use of chemotherapeutic
agents.
2. Patientsand Methods
This study was conducted on a cohort of 40 children with
ALL (18 males and 22 females) with their ages ranging
between 2 and 15 years. They were enrolled consecutively
from the recently diagnosed cases of ALL at Pediatric Hema-
tologyandOncologyUnitofMansouraUniversityChildren’s
Hospital,Mansoura,Egypt,intheperiodbetweenNovember
2006 and July 2007. Diagnosis of ALL was done according to
standard methods including morphological, cytochemical,
and immunological evaluation. Patients were treated by
the modiﬁed BFM 76/79 protocol of therapy [8]. Cases
with serious complications that may necessitate cessation
of chemotherapy for undetermined duration were excluded
fromtheselection.Patientswererandomlyallocatedintoone
of two groups. First group (Group I) included 20 patients
(10 males and 10 females) who were supplemented with
vitaminEinadose of400 IU/day orallyandN-acetylcysteine
(NAC) in a dose of 600mg/day orally [9] in addition to
chemotherapy from day one of treatment till the end of
CNS intensiﬁcation (Phase II of chemotherapy, for a period
of almost two months). CNS intensiﬁcation phase includes
a combination of chemotherapy (intrathecal methotrexate
age-adjusted doses on days 4, 11, 18, and 25) and cranial
irradiation (1800cGy in 10 fractions of 180cGy per day).
The second group (Group II) included 20 patients (8 males
and 12 females) who received chemotherapy and radiother-
apy without any supplementation. Informed consent was
obtained from the parents prior to giving chemotherapy and
any supplementation. Blood samples were collected from
every patient at day 28 of induction and at the end of CNS
intensiﬁcation for estimation of Malondialdehyde (MDA)
thiobarbituric acid reactive substance, serum glutathione
peroxidase (Glu.Px), tumor necrosis factor alpha (TNF-
α), and liver function tests (SGOT, SGPT). Blood was
collected into heparinised tubes which were protected from
light and processed immediately after sampling. At the
time of collecting the blood samples, patients were free
of any potentially confounding or interfering conditions,
such as infections, fever, derangements of glucose, and lipid
metabolism. Patients were evaluated for occurrence of any
complications, for example, haematological complications
like bone marrow (BM) hypoplasia (BM cellularity less than
30000 at the end of either induction or CNS intensiﬁcation
phases), febrile neutropenia, need for blood or platelet
transfusions(hemoglobinlevellessthan8gm/dLandplatelet
count less than 20000/cmm, resp.), and toxic hepatitis
(deﬁned by elevation of liver enzymes, 2 to 3 folds after
chemotherapy, with the exclusion of viral hepatitis and
return to the normal range after suspending chemotherapy
[10]).
2.1. Estimation of Serum Glutathione Peroxidase [11]. Glu-
tathione peroxidase (Glu.Px) was assayed by kit purchased
from Randox (Randox Laboratories Ltd., UK) (Cat. No.
RS505). This method-based on the fact that is Glu.Px
catalyses the oxidation of glutathione (GSH) by cumene
hydroperoxide.Inthepresenceofglutathionereductase(GR)
and NADPH, the oxidized glutathione (GSSG) is immedi-
ately converted to the reduced form with a concomitant
oxidation of NADPH to NADP. Then decrease in absorbance
at 340nm is measured calorimetrically.
2.2. Determination of Malondialdehyde (MDA) Thiobarbi-
t u r i cA c i dR e a c t i v eS u b s t a n c e s[ 12]. Serum proteins are
precipitated by addition of trichloroacetic acid (TCA). Then,
thiobarbituric acid (TAB) reacts with malondialdehyde
(MDA) to form thiobarbituric acid reactive product, which
is measured calorimetrically at 534nm.
2.3. Determination of Human Tumor Necrosis Factor Alpha
(TNF-α). (TNF-α) is determined by ELISA technique
(Biosource, Belgium) according to method of Beutler and
Cerami [13].
2.4. Statistical Analysis. It was done by using SPSS for
windows (Statistical Package for Social Science Version 10).
Exploration of quantitative parameters revealed violation of
normality in Glu.Px, MDA, and TNF-α, and liver enzymes
for which nonparametric test (Mann Whitney U-Wilcoxon
test) was applied with the use of median and interquartiles to
express central tendency and dispersion. However frequency
distribution of blood and platelet transfusions showed pre-
servednormality;sot-testwithmeanandstandarddeviation
was reasonable for the analysis of diﬀerence between the two
groups of patients. Number and percentages of categorical
parameters (frequency of hematological complications and
toxic hepatitis) had been done with the application of Chi
square test for analysis of the statistical signiﬁcance. P is
considered signiﬁcant if ≤.05.
3. Results
Table 1 shows the median values and interquartiles of serum
level of Glu.Px, MDA, and TNF-α in the two phases of
therapy in both leukemia groups. There is a statistically sig-
niﬁcant increase in serum Glu.Px in group I (supplemented
with vitamin E and NAC) compared to group II duringAdvances in Hematology 3
Table 1: Serum glutathione peroxidase (Glu.Px), malondialdehyde (MDA), and tumor necrosis factor-α (TNF-α) in phases I and II of
therapy for both leukemia groups.
Groups Glu.Px (U/L) MDA (nmol/mL) TNF-α (pg/mL)
After phase I After phase II After phase I After phase II After phase I After phase II
Group I
Median 925 1142 3.52 2.79 41.17 40.34
I.Q 846–973 937–1409 2.79–4.14 2.1–3.4 28.5–72.3 13.4–82.3
Group II
Median 949 936 3.57 3.32 39.29 36.25
I.Q. 810–1230 835–1012 2.84–4.23 2.75–4.42 22.1–59.9 18.9–71.8
P .43 .03 .66 .13 .52 .85
I.Q.: interquartiles (25th–75th). Signiﬁcance of Mann Whitney U-Wilcoxon Rank test if P<. 05. Phase I: intensive induction chemotherapy. Phase II: CNS
intensiﬁcation phase.
Table 2: Toxic hepatitis in both leukemia groups during phases I
and II of chemotherapy.
Group I (n = 20) Group II (n = 20) P
No % No %
After phase I 6 30.0 12 60.0 .02
After phase II 8 40.0 20 100.0 .001
Toxic hepatitis is diagnosed by elevation of liver enzymes 2-3 folds after
chemotherapy with exclusion of viral hepatitis and normalization of these
enzymeswhenchemotherapywastemporarysuspended.SigniﬁcanceofChi
square test if P<. 05.
phase II (P = .03). MDA is slightly decreased in group
I after phase II of therapy but this decrease is statistically
insigniﬁcant (P = .13). Serum level of TNF-α does not show
any signiﬁcant diﬀerence between both groups of patients
after the two phases of therapy.
The occurrence of toxic hepatitis and the serum level of
liverenzymes(SGOTandSGPT)arereportedinTables2and
3. The incidence of toxic hepatitis is signiﬁcantly lower in
group I of patients who were supplemented with vitamin E
and NAC after both phases of therapy (P = .02 and P = .001,
resp.). Similar results were found regarding the serum level
of SGOT and SGPT (P = .007, .004, .022, and .003, resp.).
Hematological complications (bone marrow hypoplasia
and febrile neutropenia) were statistically higher in group
II of patients who received chemotherapy alone without
any supplementation (P = .001) as shown in Table 4.
Frequencies of blood and platelet transfusions are lower in
group I compared to group II of patients after both phases of
therapy (P = .001 for all diﬀerences) (Table 4).
4. Discussion
Many patients with cancer take antioxidant nutritional
supplements during cancer treatment to alleviate treatment
toxicities and to improve long-term outcomes, but little is
known about the eﬃcacy and safety of antioxidant use dur-
ing cancer treatment [14]. Despite the considerable debate
about the role of antioxidant status in cancer outcomes,
very few studies have assessed changes in antioxidant status
Table 3:LiverenzymeslevelsofleukemiapatientsafterphasesIand
II of chemotherapy.
Group I (n = 20) Group II (n = 20)
Liver enzymes (U/L) Median Median P
I.Q. I.Q.
SGOT after phase I 82.39 144.2 .007
56.2–112.4 124.3–182.4
SGOT after phase II 197.4 380.4 .004
96.8–216.5 246.6–490.5
SGPT after phase I 137.58 224.1 .022
122.1–156.2 189.4–264.2
SGPT after phase I 169.5 772.5 .003
145.8–199.4 508.4–821.6
Table 4: Hematological complications (bone marrow hypoplasia
and febrile neutropenia) as well as frequency of blood and platelet
transfusions (during phases of chemotherapy) in both leukemia
groups.
Group I (n = 20) Group II (n = 20) P
Hematological
complications N (%) 8 (40) 20 (100) .001
Phase I (mean ± SD)
Blood transfusion 1.44 ±0.52 2.60 ±0.69 .001
Platelet transfusion 1.20 ±0.44 3.40 ±1.50 .001
Phase II (mean ± SD)
Blood transfusion 1.16 ±0.40 2.20 ±0.42 .001
Platelet transfusion 1.00 ±0.00 1.60 ±0.69 .001
Signiﬁcance of Chi square test (for hematological complications) and t-test
(for number of blood and platelet transfusions) if P<. 05.
and oxidative stress. Among children undergoing treatment
for cancer there was only one study, to our knowledge,
that measured exposure and treatment outcome in pediatric
oncology [15]. They found that children with ALL have
alteredantioxidantandmicronutrientstatusatdiagnosisand
during treatment. Our results support this study; oxidative
stress has been found to be increased during treatment and
antioxidant status decreased as being measured by serum4 Advances in Hematology
Glu.Px and MDA in the group of children with ALL who did
not receive antioxidants. Antioxidant status was associated
with treatment-related oxidative stress (febrile neutropenia
and elevated liver enzymes). We observed a signiﬁcant
increase of serum Glu.Px in ALL patients receiving vitamin
E and NAC after phase II of therapy in comparison to those
who received chemotherapy alone without any supplemen-
tation. Although MDA decreased after phase II of therapy
in group I of ALL patients, this decrease is not statistically
signiﬁcant; this could be explained, in part, by the relatively
small sample size. Comparison of serum level of TNF-α did
not show any diﬀerence between both groups of patients.
TheseﬁndingsareconsistentwiththeresultsofPortakalet al.
[16], Ray et al. [17], and Mantovani et al. [18] who found
an increase of oxidative stress during treatment in cancer
patients as compared with control. Thus we may conclude
that vitamin E and NAC supplementation had signiﬁcantly
decreased the level of free radicals resulting from oxidation
as evidenced by increasing the level of GLu.Px and lowering
levelofMADinALLpatientswhotookthesupplementation.
The intensity of chemotherapy taken during induc-
tion phase and CNS intensiﬁcation (vincristine, doxoru-
bicin, cytosine arabinoside, cyclophosphamide, and 6-
mercaptopurine) in addition to the prophylactic cranial
irradiation which is proven to elicit 10 times more free
radicals than chemotherapy alone leads to the increased
incidence of toxic hepatitis as evidenced by increased serum
levels of liver enzymes (SGOT and SGPT) and serum
bilirubin. Occurrence of toxic hepatitis necessitates the
interruption of treatment and prolongation of the period of
hospital stay. Our study revealed signiﬁcant decrease in the
incidence of toxic hepatitis in group I compared to group II
after induction chemotherapy (P = .02). Furthermore this
diﬀerence increased more after CNS intensiﬁcation phase of
therapy (P<. 001). Similar results had also been achieved as
regard to the serum level of SGOT and SGPT in both groups
of patients after the induction and CNS intensiﬁcation
phases of therapy (P = .007, .004, .022, and <. 003, resp.).
TheseresultssupporttheﬁndingsofMantovanietal.[19,20]
who concluded the eﬀective role of some antioxidants in
reducingreactiveoxygenspecies,proinﬂammatorycytokines
levels, and increasing Glu.Px levels in cancer patients. The
eﬀective in vivo use of NAC as antioxidant to counteract
chemotherapy and radiotherapy toxicity in cancer patients
concomitantly with vitamin E conﬁrmed the beneﬁcial eﬀect
of its in vitro use in advanced stage cancer [21].
Hematological complications including bone marrow
hypoplasia and febrile neutropenia as well as frequencies of
blood and platelet transfusion were found to be signiﬁcantly
lower in group I compared to group II throughout the
studied period (P<. 001 for all diﬀerences).
Oxidative stress increases during treatment and antiox-
idant status decreases as measured by MDA and serum
Glu.Px. With the combined use of NAC and vitamin E, some
improvement in oxidative status had occurred; this could
be considered as an encouraging result which paves the way
for early combined use of these antioxidants as an adjuvant
therapy for cancer chemotherapy. However further studies
should be contemplated to assess the long term beneﬁt of
thisadjuvanttherapyduringthemaintenancechemotherapy,
taking in consideration survival outcomes including disease-
free and overall survival, and total chemo-/radiotherapy
doses as basic parameters for evaluating the relative beneﬁts
and hazard ratios. This plan is of utmost importance,
especially because of the feasible practical application of this
adjuvant therapy being of low cost.
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